The intersection of tumor progression and chemotherapy signatures in immune cells suggest that the IL4 pathway may play a potential role in the immune surveillance of NSCLC tumorigenesis, and immune potentiation of combination chemotherapy for NSCLC. The gene discussed is IL4; the disease is non-small cell lung carcinoma.